Drug Trial Radar · NCT02554786
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma
Last checked: Nov 19, 2026Latest source record: Mar 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,216
Actual
Start
Dec 29, 2015
Primary completion
Nov 21, 2018
Study completion Jun 28, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 µg and QMF149 150/320 µg via Concept1) over two respective MF doses (MF 400 µg and MF 800 µg via Twisthaler® (total daily dose)) in poorly controlled asthmatic participants as determined by pulmonary function testing, and effects on asthma control
Conditions
- Asthma
Interventions
Indacaterol acetate/Mometasone furoateDrug
Mometasone furoateDrug
Salmeterol xinafoate/fluticasone propionateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26Time frame: 26 weeks
Locations
388 sites in 24 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Orange, California
Novartis Investigative Site
Riverside, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
San Jose, California
Novartis Investigative Site
Stockton, California
Novartis Investigative Site
Westminster, California
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Tallahassee, Florida
Novartis Investigative Site
Winter Park, Florida
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Waldorf, Maryland
Novartis Investigative Site
North Dartmouth, Massachusetts
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Bellevue, Nebraska
Novartis Investigative Site
Las Vegas, Nevada
Novartis Investigative Site
Skillman, New Jersey
Novartis Investigative Site
Cortland, New York
Novartis Investigative Site
Oklahoma City, Oklahoma
Novartis Investigative Site
Tulsa, Oklahoma
Novartis Investigative Site
Medford, Oregon
Novartis Investigative Site
Portland, Oregon
Novartis Investigative Site
Pittsburgh, Pennsylvania
Novartis Investigative Site
North Charleston, South Carolina
Novartis Investigative Site
Boerne, Texas
Novartis Investigative Site
El Paso, Texas
Novartis Investigative Site
Greenfield, Wisconsin
Novartis Investigative Site
Pleven, Bulgaria
Novartis Investigative Site
Plovdiv, Bulgaria
Novartis Investigative Site
Rousse, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Stara Zagora, Bulgaria
Novartis Investigative Site
Troyan Municipality, Bulgaria
Novartis Investigative Site
Plovdiv, BGR, Bulgaria
Novartis Investigative Site
Varna, BGR, Bulgaria
Novartis Investigative Site
Vidin, BGR, Bulgaria
Showing 40 of 388 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.